H.C. Wainwright analyst Sean Lee CFA has maintained their bullish stance on DWTX stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Lee CFA’s rating is based on several key factors surrounding Dogwood Therapeutics’ current and future prospects. A significant catalyst for the company is the anticipated interim results from the Phase 2b study of Halneuron, their leading Nav1.7 sodium channel inhibitor, which is being tested for chemotherapy-induced neuropathic pain. This study is crucial as it could provide insights into the drug’s efficacy and tolerability, with interim results expected by the fourth quarter of 2025 and full results by mid-2026. The low discontinuation rate among the first batch of patients suggests promising tolerability, and the study’s progress could influence future patient recruitment and study expansion.
Financially, Dogwood Therapeutics reported a net loss in the second quarter of 2025, aligning with consensus estimates, and holds sufficient cash reserves to fund operations into the second quarter of 2026. Despite the lack of current revenues, the company’s valuation is supported by a risk-adjusted net present value analysis of its product pipeline, leading to a 12-month price target of $10. This valuation, combined with the potential of their lead product and strategic plans for a Phase 3 study, underpins the Buy rating. However, potential risks include clinical, regulatory, and financial uncertainties that could impact future performance.
According to TipRanks, Lee CFA is an analyst with an average return of -1.1% and a 33.51% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Senseonics Holdings, Plus Therapeutics, and Verastem.
In another report released on August 13, Maxim Group also maintained a Buy rating on the stock with a $30.00 price target.